News

DIAN Biotech showcased its comprehensive AI-assisted digital pathology diagnostic solutions at the prestigious exhibition Medlab Middle East hold in Dubai. And the whole solution attracted a lot of visitors stop by and inquired for potential cooperation. Existing distributors stopped by for deeper cooperation details, meanwhile, potential distributors passed by and were interested in the solutions we provide. >>Automatic Liquid-based cytology slide prep and staining system: 1. Fully automated to reduce workload. 2. Combines multiple functions in one instrument with small footprint. 3. CE certified both for instrument, reagent and consumables. 4. Innovative technology is applied to ensure stable performance. >> Digital pathology slide scanner 1. Various capacities, small, medium and large throughput are available. 2. Convert physical slide into digital image to promote digitalization in pathology industry. 3. User-friendly and easy operation, enhance work efficiency. 4. Achieve telepathology and remote education for hospitals and institutions. >> AI-assisted diagnostic software 1. Can automatically generate report within 1 minute 2. With pretty high efficiency of est. 99.6% for cervical cancer screening 3. Decrease subjective mistake and increase women`s wellbeing via efficient screening About Us: DIAN Diagnostic Group was found in 1996, listed in 2011 (Stock No.300244), around USD 3 billion sales revenue in 2022, over 10K employees and 42 ICL in China. DIAN biotech is the holding subsidiary of DIAN Diagnostic group, and is devoted to in-house R&D, manufacture, international sales and technical service. Its factory is ISO 13485 certified and complies to GMP standards, and it is equipped with 11,000 m² factory size for production, over 11 automated production lines to ensure annual production capacity up to 600 million tests. Served over 17,000 medical institutions all over China, DIAN Biotech is exploring international market with its digital and Ai-assisted pathology diagnostic solutions for worldwide health concern.

January 9th, 2022, is a real red-letter day for GENEDIAN since it`s both the company`s 8th anniversary as well as factory-warming ceremony. GENEDIAN upgraded manufacturing site and equipments to expand production capacity with automated and state-of-the-art facilities. Today, all devoted distributors across the country gathered together in GENDIAN with their respective sales representatives to express their sincere congratulations as well as expectations for further business cooperation. The most impressive part is the panel held by the well-known scholars and celebrities of pathology, clinical lab and AI area, leading us to have a deeper and more comprehensive sight of the development trend for the combination of AI and Diagnostics. Wishing GENEDIAN a more prosperous 2022!

At the press conference held on February 15, DIAN Diagnostics (China stock market code: 300244) has become the Official Exclusive Supplier for the 19th Asian Games and the 4th Asian Para Games in Hangzhou 2022, and will provide health testing related services for the Games. Olympic champion Zhu Qinan, also as Party member of Hangzhou Asian Organizing Committee and director of competition department, together with Chen Haibin, chairman of DIAN Diagnostics attended the press conference. Du Mengfei, vice director of market development department of Hangzhou Asian Organizing Committee and Yao Shuli, vice president of DIAN Diagnostics signed the agreement on behalf of both parties. As a comprehensive medical diagnostics service provider, DIAN Diagnostics established 40 chain laboratories and served 20 thousand+ medical institutions and over 300 million customers. To fulfill the mission of achieving "Equal Acess To Healthcare", DIAN Diagnostics is committed to play an active role in COVID-19 diagnosis and epidemic perevention with its accumulated over 25 years` experience in health industry and will provide professional health testing services for the Games in Hangzhou. In abroad, Hangzhou DIAN Biotechnology Co., Ltd (brand: GENEDIAN), an innovative IVD company and wholly owned subsidiary of DIAN Diagnostics, is providing integrated solutions to combat SARS-CoV-2 with COVID-19 Antigen Rapid Test Cassette, both Professional Use and Self-Testing, as well as Real Time PCR Detection systems for worldwide heath concerns.

At the press conference held on February 15, DIAN Diagnostics (China stock market code: 300244) has become the Official Exclusive Supplier for the 19th Asian Games and the 4th Asian Para Games in Hangzhou 2022, and will provide health testing related services for the Games. Olympic champion Zhu Qinan, also as Party member of Hangzhou Asian Organizing Committee and director of competition department, together with Chen Haibin, chairman of DIAN Diagnostics attended the press conference. Du Mengfei, vice director of market development department of Hangzhou Asian Organizing Committee and Yao Shuli, vice president of DIAN Diagnostics signed the agreement on behalf of both parties. As a comprehensive medical diagnostics service provider, DIAN Diagnostics established 40 chain laboratories and served 20 thousand+ medical institutions and over 300 million customers. To fulfill the mission of achieving "Equal Acess To Healthcare", DIAN Diagnostics is committed to play an active role in COVID-19 diagnosis and epidemic perevention with its accumulated over 25 years` experience in health industry and will provide professional health testing services for the Games in Hangzhou. In abroad, Hangzhou DIAN Biotechnology Co., Ltd (brand: GENEDIAN), an innovative IVD company and wholly owned subsidiary of DIAN Diagnostics, is providing integrated solutions to combat SARS-CoV-2 with COVID-19 Antigen Rapid Test Cassette, both Professional Use and Self-Testing, as well as Real Time PCR Detection systems for worldwide heath concerns.

To combat with the pandemic in European Area, GENEDIAN prepared remarkable quantity of COVID-19 Antigen Rapid Test Cassettes in German warehouse for local supply and quick delivery.

GENEDIAN SARS-CoV-2 Antigen Rapid Test Device was officially Included in HSC Common List, issued by European Commission Directorate – General for Health and Food Safety on Dec. 23, 2021. This is another international authoritative certification for this product after obtaining CE certification, BfArM List and PEI verification in Germany. About GENEDIAN COVID-19 Antigen Rapid Test Cassette: Rapid result:Results to read at 15 min. Easy of use:No need of equipment Storage:Room temperature storage, 24 months shelf life. Performance:Sensitivity(97.6%), specificity(98.4%) Specimen: Both Anterior Nasal Swab and Nasopharyngeal Swab

On 26 November 2021, WHO designated the variant B.1.1.529 (named Omicron) a variant of concern (VOC). Omicron is a highly divergent variant with a high number of mutations, including 26‐32 in the spike, some of which are concerning and may be associated with immune escape potential and higher transmissibility. The overall global risk related to the new VOC Omicron is assessed as very high. In quick response to the Novel Coronavirus variant Omicron, GENEDIAN`s bioinformatics experts urgently analyzed and compared the mutation points with the detection areas of our existing products and officially announce that GENEDIAN`s existing assay, CE marked, are qualified and efficient to detect the Omicron: 1. GENEDIAN® COVID-19 Antigen Test Cassette(Rapid Test) 2. GENEDIAN® Novel Coronavirus (SARS-CoV-2) Nucleic Acid Detection Kit (PCR-Fluorescence Probing) 3. GENEDIAN® POC SARS-CoV-2 Nucleic Acid Detection Kit GENEDIAN`s comprehensive COVID-19 diagnosis solutions are also experimentally proved qualified for detecting the variants of concern recently designated by WHO, including but not limited to Alpha(B.1.1.7+Q.x).Beta(B.1.351+B.1.351.2+B.1.351.3).Gamma(P.1+P.1.x).Delta(B.1.617.2+AY.x).Eta(B.1.525).Iota(B.1.526).Kappa(B.1.617.1).Lambda(C.37+C.37.1).Zeta(P.2).Epsilon(B.1.429+B.1.427).Mu(B.1.621+B.1.621.1).N.9.B.1.640. GENEDIAN has been paying close attention to the mutation of COVID-19 to upgrade our products accordingly to ensure high specificity and sensitivity for worldwide healthcare.